{
  "study_type": "Retrospective Cohort Study",
  "description": "Study to evaluate the association between benzodiazepine exposure and mortality",
  "analyses": [
    {
      "part": 1,
      "title": "Hospitalized COVID-19 Patients",
      "objective": "Assess the impact of benzodiazepine exposure on survival among hospitalized COVID-19 patients",
      "index_date": "Date of COVID-19 diagnosis or positive test result",
      "inclusion_criteria": [
        "Patients hospitalized with confirmed COVID-19 (via diagnosis or positive test)",
        "Received alprazolam, diazepam, lorazepam, or clonazepam within 30 days prior to the index date"
      ],
      "control_group": "Hospitalized COVID-19 patients with no exposure to any benzodiazepines within 30 days prior to the index date",
      "covariates": [
        "Age",
        "Sex",
        "Comorbidities",
        "COVID-19 severity"
      ]
    },
    {
      "part": 2,
      "title": "Patients with a History of Cancer",
      "objective": "Evaluate the effect of benzodiazepine exposure on survival in patients with a history of cancer",
      "index_date": "Date of cancer diagnosis (or another relevant date, e.g., start of treatment)",
      "inclusion_criteria": [
        "Patients with a documented history of cancer",
        "Received alprazolam, diazepam, lorazepam, or clonazepam within 30 days prior to the index date"
      ],
      "control_group": "Patients with a history of cancer and no exposure to any benzodiazepines within 30 days prior to the index date",
      "covariates": [
        "Age",
        "Sex",
        "Comorbidities",
        "Cancer stage",
        "Cancer type"
      ],
      "stratification": [
        "Pancreatic cancer",
        "Brain cancer",
        "Lung cancer",
        "Breast cancer"
      ],
      "stratification_condition": "if sample size permits"
    }
  ],
  "common_design_elements": {
    "event_of_interest": "Death",
    "censoring": [
      "Loss to follow-up",
      "Last date of encounter",
      "End of study period"
    ],
    "time_scale": "Days from the index date",
    "primary_exposure": "Use of alprazolam, diazepam, lorazepam, or clonazepam within 30 days prior to the index date",
    "outcome": "Time to death, with censoring as specified"
  },
  "analysis_methods": {
    "primary_analysis": "Cox proportional hazards model, adjusted for specified covariates",
    "clustering_adjustment": "Mixed-effects Cox model to account for hospital-level clustering",
    "visual_comparison": "Kaplan-Meier curves to compare survival across benzodiazepine types",
    "statistical_tests": "Log-rank test for overall survival differences among exposure groups",
    "sensitivity_analyses": [
      "Competing risks analysis (e.g., using Fine-Gray models)",
      "Restricted mean survival time (RMST) as an alternative survival metric",
      "Varying exposure windows (e.g., 15 or 60 days prior to the index date)"
    ]
  },
  "data_management": {
    "data_cleaning": [
      "Standardize date formats and drug codes using OMOP concept sets",
      "Validate cancer diagnosis codes and COVID-19 diagnosis/test results",
      "Ensure accurate exposure windows (within 30 days prior to the index date)",
      "Check follow-up completeness and eliminate implausible values"
    ],
    "missing_data_strategy": {
      "mar": "Apply multiple imputation using available covariates (e.g., age, demographics)",
      "mnar": "Conduct sensitivity analyses under varying assumptions about missingness mechanisms to assess result robustness"
    }
  },
  "statistical_considerations": {
    "power_analysis": {
      "significance_level": 0.05,
      "desired_power": 0.80,
      "purpose": "Calculate sample size requirements for subgroup analyses"
    },
    "proportional_hazards": "Test using Schoenfeld residuals; consider time-varying covariates if violated",
    "competing_risks": "Account for non-death events (e.g., discharge or recovery) that may preclude the outcome of interest",
    "sensitivity_analysis": "Explore different exposure time windows to ensure findings are robust"
  },
  "data_quality_control": [
    "Validate death dates against other clinical events",
    "Verify temporal relationships (e.g., no future dates relative to the index date)",
    "Confirm drug exposure within the 30-day window prior to the index date",
    "Check for concurrent prescriptions or treatment changes that may confound exposure classification",
    "Validate medication dosing where data are available"
  ]
}
